Versicor begins anidulafungin Phase II study

VERS began an open-label U.S. Phase II trial of its anidulafungin (formerly V-Echinocandin), an inhibitor of fungal cell wall synthesis, in 120 hospitalized patients diagnosed with invasive candiadias...